Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs)

Dementia Clinical Trial

— RDAD  

Official title:

From Evidence-Base to Practice: Implementing RDAD in AAA Community-Based Services

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01708304
• Other study ID #: 41906
• Status: Completed
• Phase: N/A
• First received: October 9, 2012
• Last updated: September 14, 2017
• Start date: November 2012
• Est. completion date: June 2017

Study information

• Verified date: September 2017
• Source: University of Washington
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The University of Washington's Northwest Research Group on Aging is partnering with Area Agencies on Aging (AAA) in Washington and Oregon to complete this translational investigation of RDAD (Reducing Disabilities in Alzheimer's Disease). RDAD is an evidence-based program with demonstrated efficacy in helping older adults with dementia maintain physical function and remain physically and mentally healthy. This study asks two questions: 1) Can AAA partners successfully translate and implement RDAD, and 2) Is AAA implementation of RDAD effective in producing desired outcomes among agencies, providers, and older adults with dementia and their family members. This study is being conducted in Washington and Oregon states.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 510
• Est. completion date: June 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

Care Recipients must

• Have a diagnosis of dementia

• Be 65 years of age or older

• Currently exercise no more than 150 minutes a week and not regularly participate in a formal exercise program.

Caregivers must

• Live in the community

• Provide care to the care recipient with dementia

Exclusion Criteria:

Either Care-recipient or Caregiver must not

• Plan to move to a long-term residential care setting within 6 months of enrollment.

• Plan to move from the study geographic area within 4 months of enrollment.

• Have a known terminal illness (with death anticipated within the next 12 months)

• Have had a hospitalization for a psychiatric disorder in the 12 months prior to baseline

• Be actively suicidal, hallucinating, or delusional

• Be blind, deaf, or not ambulatory

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease
• Cognition Disorders
• Cognitive Impairment
• Dementia
• Memory Impairment

Intervention

Behavioral:
• RDAD
Exercise training for caregiver and care recipient. Behavioral modification training for caregiver.

Locations

Country	Name	City	State
United States	University of Washington	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
University of Washington

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Minutes of exercise per week	Caregivers will track the number of minutes per week the care recipients engage in exercise recommended by the coach.	Change from baseline in number of minutes of exercise each week during treatment phase of study, weeks 7-12
Primary	Restricted Activity Days	Restricted Activity Days measures how much the participant cut down his/her usual activities in the previous two weeks because of injury or illness and how many days the participant stayed in bed in the previous two weeks because of injury or illness.	Baseline
Primary	Restricted Activity Days	Restricted Activity Days measures how much the participant cut down his/her usual activities in the previous two weeks because of injury or illness and how many days the participant stayed in bed in the previous two weeks because of injury or illness.	Change from Baseline to Pre-Treatment (6 weeks)
Primary	Restricted Activity Days	Restricted Activity Days measures how much the participant cut down his/her usual activities in the previous two weeks because of injury or illness and how many days the participant stayed in bed in the previous two weeks because of injury or illness.	Change from Baseline to Post- Treatment 1 (13 weeks)
Primary	Restricted Activity Days	Restricted Activity Days measures how much the participant cut down his/her usual activities in the previous two weeks because of injury or illness and how many days the participant stayed in bed in the previous two weeks because of injury or illness.	Change from Baseline to Post-Treatment 2 (30 weeks)
Primary	Restricted Days of Activity	Restricted Activity Days measures how much the participant cut down his/her usual activities in the previous two weeks because of injury or illness and how many days the participant stayed in bed in the previous two weeks because of injury or illness.	Change from Baseline to 13 Month Follow-Up
Primary	Independence/Residential Status	All participants will be in independent living situations at baseline. Any move from independent living to a care facility will be documented throughout the 13 month study.	Change from Baseline to 13 Month Follow-Up
Secondary	Revised Memory and Behavior Problem Checklist (RMBPC)	Checklist rates 24 care recipient behaviors for frequency of occurrence and caregiver reaction.	Baseline
Secondary	Revised Memory and Behavior Problem Checklist (RMBPC)	Checklist rates 24 care recipient behaviors for frequency of occurrence and caregiver reaction.	Change from Baseline to Pre-Treatment (6 weeks)
Secondary	Revised Memory and Behavior Problem Checklist (RMBPC)	Checklist rates 24 care recipient behaviors for frequency of occurrence and caregiver reaction.	Change from Baseline to Post-Treatment 1 (13 weeks)
Secondary	Revised Memory and Behavior Problem Checklist (RMBPC)	Checklist rates 24 care recipient behaviors for frequency of occurrence and caregiver reaction.	Change from Baseline to Post-Treatment 2 (30 weeks)
Secondary	Revised Memory and Behavior Problem Checklist (RMBPC)	Checklist rates 24 care recipient behaviors for frequency of occurrence and caregiver reaction.	Change from Baseline to 13 Month Follow-Up
Secondary	Quality of Life-AD	This 13-item measure is specifically designed for individuals with dementia and focuses on quality of life domains identified as important for cognitively impaired older adults.	Baseline
Secondary	Quality of Life-AD	This 13-item measure is specifically designed for individuals with dementia and focuses on quality of life domains identified as important for cognitively impaired older adults.	Change from Baseline to Pre-Treatment (6 weeks)
Secondary	Quality of Life-AD	This 13-item measure is specifically designed for individuals with dementia and focuses on quality of life domains identified as important for cognitively impaired older adults.	Change from Baseline to Post-Treatment 1 (13 weeks)
Secondary	Quality of Life-AD	This 13-item measure is specifically designed for individuals with dementia and focuses on quality of life domains identified as important for cognitively impaired older adults.	Change from Baseline to Post-Treatment 2 (30 weeks)
Secondary	Quality of Life-AD	This 13-item measure is specifically designed for individuals with dementia and focuses on quality of life domains identified as important for cognitively impaired older adults.	Change from Baseline to 13 Month Follow-Up
Secondary	CES-D	This 20-item scale that assesses depression in caregivers.	Baseline
Secondary	CES-D	A 20-item scale that assesses depression in caregivers.	Change from Baseline to Pre-Treatment (6 weeks)
Secondary	CES-D	A 20-item scale that assesses depression in caregivers.	Change from Baseline to Post-Treatment 1 (13 weeks)
Secondary	CES-D	A 20-item scale that assesses depression in caregivers.	Change from Baseline to Post-Treatment 2 (30 weeks)
Secondary	CES-D	A 20-item scale that assesses depression in caregivers.	Change from Baseline to 13 Month Follow-Up